Shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokers have set a 1-year consensus price target of $40.25 for the company and are forecasting that the company will post ($1.01) earnings per share for the current quarter, according to Zacks. Zacks has also assigned CoLucid Pharmaceuticals an industry rank of 105 out of 265 based on the ratings given to its competitors.
A number of brokerages recently weighed in on CLCD. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $21.00 price objective on shares of CoLucid Pharmaceuticals in a report on Friday, September 9th. Zacks Investment Research lowered CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, June 8th. Finally, Ladenburg Thalmann set a $57.00 price objective on CoLucid Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 19th.
In related news, major shareholder A/S Novo acquired 100,000 shares of CoLucid Pharmaceuticals stock in a transaction dated Friday, September 9th. The shares were acquired at an average cost of $20.00 per share, for a total transaction of $2,000,000.00. Following the completion of the transaction, the insider now directly owns 3,156,563 shares of the company’s stock, valued at $63,131,260. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Thomas P. Mathers sold 1,502 shares of the company’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $37.08, for a total value of $55,694.16. Following the completion of the sale, the chief executive officer now owns 248,169 shares in the company, valued at $9,202,106.52. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of CLCD. Societe Generale bought a new stake in shares of CoLucid Pharmaceuticals during the second quarter valued at about $464,000. FMR LLC bought a new stake in shares of CoLucid Pharmaceuticals during the second quarter valued at about $554,000. Finally, Vanguard Group Inc. increased its stake in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 900 shares in the last quarter. Institutional investors and hedge funds own 30.47% of the company’s stock.
CoLucid Pharmaceuticals (NASDAQ:CLCD) traded down 0.24% on Thursday, hitting $36.87. The stock had a trading volume of 107,695 shares. CoLucid Pharmaceuticals has a one year low of $3.60 and a one year high of $39.27. The stock’s 50 day moving average is $22.05 and its 200 day moving average is $11.05. The stock’s market cap is $565.36 million.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last announced its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.22. Analysts anticipate that CoLucid Pharmaceuticals will post ($3.91) earnings per share for the current year.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.